Concarlo Therapeutics

About:

Concarlo Therapeutics is a preclinical-stage oncology company developing transformative therapeutics to target drug-resistant cancers.

Website: https://concarlo.com/

Top Investors: New York State, THE CATALYTIC IMPACT FOUNDATION (CIF), Accelerate New York Seed Fund, Various Investors

Description:

Concarlo Therapeutics is a preclinical-stage oncology company developing transformative therapeutics to target drug-resistant cancers. Concarlo’s vision is to create a world of possibility and time, where cancer is a treatable, manageable, and survivable condition. Concarlo is developing therapies to drug p27, the natural inhibitor of CDK4/CDK6 and CDK2. The company is harnessing decades of research to target a unique cellular pathway to kill – not just stop – the growth of tumor cells. Concarlo is leveraging its deep understanding of this pathway to develop new treatments for a wide range of advanced and drug-resistant cancers.